Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nonalcoholic steatohepatitis (NASH)
Biotech
Ligand tries to disembark from Viking pact, alleging breach
Viking Therapeutics’ collaboration with Ligand has sailed into some trouble, with one of the partners keen to jettison part of the pact.
James Waldron
May 1, 2026 8:31am
Gilead culls last MASH program, 2 cancer assets
Aug 8, 2025 11:50am
Researchers ID potential MASH target by disrupting mouse gene
Mar 13, 2025 1:52pm
Aligos MASH prospect slashes liver fat in phase 2
Sep 19, 2024 1:00pm
Viking's MASH drug scores where Madrigal's didn't
Jun 4, 2024 1:51pm
Boehringer signs $1.3B MASH collab with RNA biotech Ochre
Apr 22, 2024 8:45am
